- Home
- CNR vs TVTX Comparison
CNR vs TVTX Comparison
Compare CNR & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNR | TVTX |
|---|---|---|
| Founded | 1864 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.7B |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CNR | TVTX |
|---|---|---|
| Price | $83.14 | $51.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $110.50 | $73.43 |
| AVG Volume (30 Days) | 492.3K | ★ 2.2M |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $2,236,311,000.00 | N/A |
| Revenue This Year | $8.38 | $55.96 |
| Revenue Next Year | $1.81 | $48.63 |
| P/E Ratio | $26.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $73.31 | $22.59 |
| 52 Week High | $114.80 | $68.73 |
Technical Indicators
Market Signals| Indicator | CNR | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 46.58 |
| Support Level | $81.04 | $49.46 |
| Resistance Level | $91.79 | $59.93 |
| Average True Range (ATR) | 4.03 | 2.67 |
| MACD | -0.53 | 0.46 |
| Stochastic Oscillator | 48.83 | 78.41 |
Price Performance
Historical ComparisonAbout CNR Core Natural Resources Inc.
Core Natural Resources Inc is a producer and exporter of metallurgical and thermal coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The activities of the company involves mining of thermal coal, power generation, and other related activities.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.